Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma

Cancer Science

Volumn 98, Issue 4, 2007, Pages 491-498

  Betsunoh, Hironori ^a,b   Mukai, Shoichiro ^a,b   Akiyama, Yutaka ^a   Fukushima, Tsuyoshi ^a   Minamiguchi, Naoki ^c   Hasui, Yoshihiro ^b   Osada, Yukio ^b   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Koga General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; HEPSIN; MATRIPTASE; MEMBRANE PROTEIN; MESSENGER RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; KIDNEY SURGERY; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; SEQUENCE ANALYSIS; TISSUE DISTRIBUTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SERINE ENDOPEPTIDASES; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 34147123126     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00412.x     Document Type: Article

References (45)

1. Netzel-Arnett S, Hooper JD, Szabo R et al. Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metast Rev 2003; 22: 223-36.
2. List K, Szabo R, Molinolo A, Sriuranpong V et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005; 19: 1934-50.
3. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004; 6: 185-95.
4. Vasioukhin V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 2004; 3: 1394-7.
5. Stephan C, Yousef GM, Scorilas A et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004; 171: 187-91.
6. Xuan JA, Schneider D, Toy P et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 2006; 66: 3611-19.
7. Tanimoto H, Yan Y, Clarke J et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997; 57: 2884-7.
8. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36 720-5.
9. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26 333-42.
10. Kazama Y, Hamamoto T, Foster DC, Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 1995; 270: 66-72.
11. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 2005; 579: 1945-50.
12. Jiang WG, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/ scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999; 29: 209-48.
13. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metast Rev 2003; 22: 223-36.
14. Kataoka Itoh H, Hamasuna R, Meng JY, Koono M. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/GF) in colorectal carcinomas: Roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1). Hum Cell 2001; 16: 83-93.
15. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter in colorectal carcinoma. Cancer Res 2000; 60: 6148-59.
16. Tjin EP, Derksen PW, Kataoka H, Spaargaren M, Pals ST. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 2004; 104: 2172-5.
17. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 2004; 171: 890-6.
18. Shimomura T, Kondo J, Ochiai M et al. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 1993; 268: 22 927-32.
19. Kataoka H, Shimomura T, Kawaguchi T et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40 453-62.
20. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18 237-42.
21. Kawaguchi T, Qin L, Shimomura T et al. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 27 558-64.
22. Delaria KA, Muller DK, Marlor CW et al. Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 1997; 272: 12 209-14.
23. Hamasuna R, Kataoka H, Meng JY et al. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: Implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer 2001; 93: 339-45.
24. Fukai K, Yokosuka O, Chiba T et al. Hepatocyte growth factor activator inhibitor 2/placental bikunin HAI-2/PB gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res 2003; 63: 8674-9.
25. Tanaka H, Nagaike K, Takeda N et al. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Mol Cell Biol 2005; 25: 5687-98.
26. Mitchell KJ, Pinson KI, Kelly OG et al. Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet 2001; 28: 241-9.
27. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131-3.
28. Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
29. Foster K, Prowse A, van den Berg A et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal cell carcinoma. Hum Mol Genet 1994; 3: 2169-73.
30. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-4.
31. Horie S, Aruga S, Kawamata H, Okui N, Kakizoe T, Kitamura T. Biological role of HGF/MET pathway in renal cell carcinoma. J Urol 1999; 161: 990-7.
32. Koochekpour S, Jeffers M, Wang PH et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999; 19: 5902-12.
33. Tsuji A, Torres-Rosado A, Arai T et al. Hepsin, a cell membrane-associated protease. J Biol Chem 1991; 266: 16 948-53.
34. Eble JN, Sauter G, Epstein JI et al. World Health Organization classification of tumours: Pathology and genetics of tumours of the urinary system and male genital organs. Lyons: IARC Press; 2004.
35. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th edn. Philadelphia: Lippincott-Raven; 2002.
36. Muraoka K, Kataoka H, Nabeshima K et al. Establishment and characterization of a human renal cell carcinoma cell line MRT-1, with special reference to the production of serine proteinase inhibitors. Hum Cell 1995; 8: 11-18.
37. Uchinokura S, Miyata S, Fukushima T et al. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int J Cancer 2006; 118: 583-92.
38. Torres-Rosado A, O'Shea KS, Tsuji A, Chou SH, Kurachi K. Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci USA 1993; 90: 7181-5.
39. Zacharski LR, Ornstein DL, Memoli VA, Rousseau SM, Kisiel W. Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost 1998; 79: 876-7.
40. Roemer A, Schwettmann L, Jung M et al. The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J Urol 2004; 172: 2162-6.
41. Herter S, Piper DE, Aaron W et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005; 390: 125-36.
42. Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF. Expression of serine protease matriptase in renal cell carcinoma: Correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 2006; 14: 65-72.
43. Kataoka H, Itoh H, Uchino H et al. Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas. Cancer Lett 2000; 148: 127-34.
44. Muller-Pillasch F, Wallrapp C, Bartels K et al. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim Biophys Acta 1998; 1395: 88-95.
45. Morris MR, Gentle D, Abdulrahman M et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/spint2 in papillary and clear renal cell carcinoma. Cancer Res 2005; 65: 4598-606.